Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
DR REDDYS LABORATORIES LTD director Satish K Reddy reports his existing equity ownership in a Form 3. He holds 10,107,505 equity shares directly. Indirectly, he is shown with 27,618,385 equity shares via Kallam Satish Reddy HUF and 75,630,620 equity shares via the VSD Family Trust as trustee. This filing records holdings and does not show any new buying or selling activity.
DR REDDYS LABORATORIES LTD director G V Prasad has filed an initial insider ownership report showing indirect holdings of the company’s equity shares. The filing lists 12,717,090 equity shares held through “Gunupati Venkateswara Prasad HUF” and 96,095,920 equity shares held through the “GVP Family Trust (as a Trustee)”. These are reported as indirect positions rather than personal direct holdings and do not reflect any new buy or sell transactions.
Dr. Reddy’s Laboratories Limited has received three orders from the GST Authority covering FY 2019-20 to FY 2021-22, raising tax demands with interest and penalties on the ground that certain supplies are taxable in nature.
The penalties total ₹2,19,48,944 for FY 2019-20, ₹50,406 for FY 2020-21, and ₹4,384 for FY 2021-22. The company states that, based on its evaluation, these orders have no material impact on its financials, operations, or other activities and it will evaluate filing an appeal with the appellate authority.
Dr. Reddy’s Laboratories reports that its partner Immutep has halted the TACTI-004 Phase III trial of Eftilagimod alfa in first-line non-small cell lung cancer. An independent data monitoring committee recommended discontinuation after a planned interim futility analysis reviewing safety and efficacy data.
Enrollment in the study will stop and Immutep will wind down the trial while following patients and closing sites. Dr. Reddy’s subsidiary, which holds exclusive rights to develop and commercialize Eftilagimod alfa in many territories outside North America, Europe, Japan and Greater China, has so far made only the upfront payment under the collaboration and is in discussions with Immutep on the path forward.
Dr. Reddy’s Laboratories Limited reported the allotment of 10,275 equity shares of Re.1 each on March 12, 2026 to eligible employees who exercised stock options under its 2002 ESOP and 2007 ADR stock option schemes.
Following this issuance, total issued shares are stated as 83,46,54,295, and total issued share capital is Rs. 83,46,54,295/-. The company notes total paid-up capital of 83,46,53,295 equity shares of Re.1 each, aggregating to Rs. 83,46,53,295/-, with a difference of 1,000 shares due to historical forfeiture in 1988. The newly allotted shares are equity shares that rank pari passu with existing shares.
Dr. Reddy’s Laboratories responded to media reports about a Delhi High Court decision involving Semaglutide products and a dispute with Novo Nordisk. The company explains that the court’s Division Bench upheld an earlier order allowing it to manufacture Semaglutide in India and export it to countries where Novo Nordisk does not hold a patent registration, while refusing an interim injunction on Semaglutide products. Dr. Reddy’s emphasizes that the litigation remains sub judice and that, in its view, there is currently no material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations.
Dr. Reddy’s Laboratories Limited has approved a key senior leadership change. Based on the Nomination, Governance and Compensation Committee’s recommendation, the Board has elevated M S Madhu Sundar, currently Head Global Manufacturing FTO Oral Solid Dosages and Operational Excellence, to Global Head of Quality and PV, Senior Management Personnel and Member of the Management Council, effective April 1, 2026.
Madhu Sundar brings 28 years of industrial experience in API and dosage form manufacturing, quality, regulatory affairs and supply chain, and joined the company in October 2017. The company is also revising roles of other senior leaders from April 1, 2026, including appointing M V Ramana as CEO Global Generics, Sanjay Sharma as Chief Operating Officer, Krishna Venkatesh as Global Head of IPDO, and Patrick Aghanian as Head – Consumer Health Organization.
Dr. Reddy’s Laboratories Limited reports that the U.S. Department of Justice has closed its inquiry into alleged improper payments to healthcare professionals under the Foreign Corrupt Practices Act and has not recommended any enforcement action against the company. This follows an earlier letter from the U.S. Securities and Exchange Commission stating it had concluded a related investigation and did not intend to recommend enforcement. These outcomes relate to an anonymous complaint first disclosed in 2020 and formally notified to U.S. and Indian regulators, and they remove the risk of FCPA enforcement actions based on the investigated matters.
Dr. Reddy’s Laboratories Limited reports the outcome of a United States Food & Drug Administration inspection at its formulations manufacturing facility FTO-SEZ PU01 in Srikakulam, Andhra Pradesh. The company has received the Establishment Inspection Report on March 4, 2026.
The USFDA classified the inspection outcome as “Voluntary Action Indicated (VAI)” and stated that the inspection is officially closed under 21 CFR 20.64(d)(3). This update follows an earlier intimation dated December 12, 2025 about the same GMP and Pre-Approval Inspection.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its upcoming schedule of analyst and institutional investor meetings. The company’s management plans to participate in two group meetings with investors in early March 2026.
On March 4, 2026, management will attend an in-person group meet organized by Ambit Capital in Hyderabad from 11:00 to 13:30 IST. On March 5, 2026, they will join a virtual group meet organized by Goldman Sachs from 11:15 to 12:15 IST. The company notes that this schedule may change due to any exigencies on the part of investors or the company.